RCUS - Arcus Biosciences, Inc.

NYSE - NYSE Delayed Price. Currency in USD
11.89
+1.14 (+10.60%)
At close: 4:02PM EST

11.89 0.00 (0.00%)
After hours: 4:57PM EST

Stock chart is not supported by your current browser
Previous Close10.75
Open10.83
Bid8.71 x 800
Ask12.09 x 4000
Day's Range10.39 - 11.98
52 Week Range8.57 - 22.10
Volume95,775
Avg. Volume210,337
Market Cap528.554M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.05
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.75
Trade prices are not sourced from all markets
  • Business Wire2 days ago

    Arcus Biosciences Announces Participation at Upcoming Investor Conference

    Arcus Biosciences, Inc. (RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that Terry Rosen, Ph.D., Chief Executive Officer, will participate in a fireside chat at the 8th Annual Leerink Partners Global Healthcare Conference on Wednesday, February 27, 2019 at 11:30 am ET at the Lotte New York Palace, in New York, NY. Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies. Arcus has several programs targeting important immuno-oncology pathways, including a dual adenosine receptor antagonist AB928, which is in a Phase 1/1b program to evaluate AB928 in combination with other agents in multiple tumor types, and an anti-PD-1 antibody AB122, which is being evaluated in a Phase 1 trial and is being tested in combination with Arcus’s other product candidates.

  • Why Arcus Biosciences, Eldorado Gold, and Esperion Therapeutics Slumped Today
    Motley Foollast month

    Why Arcus Biosciences, Eldorado Gold, and Esperion Therapeutics Slumped Today

    Even in a surging market, these stocks fell. Find out why.

  • Business Wirelast month

    Arcus Biosciences Announces Transition of Chief Financial and Operating Officer

    Arcus Biosciences, Inc. (RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that Jennifer Jarrett will step down as the Company’s Chief Financial and Operating Officer, effective January 11, 2019, to pursue an opportunity at a privately-held transportation and technology company. Ms. Jarrett will remain actively engaged with the Company and has been appointed to Arcus’s Board of Directors commencing January 12, 2019. Ms. Jarrett and the Company have also entered into a consulting agreement that will ensure a seamless transition.

  • American City Business Journalslast month

    Here are the winners and losers from Bay Area's IPO class of 2018

    Most stocks from last year's class of Bay Area IPO companies ended the year in positive territory, with 23 of them closing 2018 above their IPO offering prices. Here's a look at all of them, as Wall Street volatility threatens the planned 2019 IPOs of a number of the most closely watched startups.

  • This year's Bay Area IPO batch remains up 44% despite market turbulence
    American City Business Journals2 months ago

    This year's Bay Area IPO batch remains up 44% despite market turbulence

    Stocks from eight of the 34 companies from the region that went public this year are now below their IPO price. Six others are trading at double or more where they started.

  • Business Wire3 months ago

    Arcus Biosciences Presents Initial Data from the Phase 1 Dose-Escalation Study of AB122, its anti-PD-1 antibody, at the SITC 2018 Annual Meeting

    Arcus Biosciences, Inc. (RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced preliminary data from its ongoing Phase 1 dose-escalation study of AB122. The data are being presented today during a poster presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C. “Preclinical data previously demonstrated that AB122 has biological, pharmacokinetic and pharmacodynamic properties similar to those of the approved anti-PD-1 antibodies and the dose-escalation data presented today represent an important step in confirming these results in patients,” said Joyson Karakunnel, MD, MSc, FACP, Vice President of Clinical Development at Arcus.

  • Business Wire3 months ago

    Arcus Biosciences Announces Third Quarter 2018 Financial Results and Recent Corporate Updates

    - Three dose-escalation trials evaluating AB928, the Company’s dual adenosine receptor antagonist, in combination with other agents are now enrolling patients; Initial data from th

  • Business Wire3 months ago

    Arcus Biosciences Announces Participation at Three Investor Conferences in November

    Arcus Biosciences, Inc. , a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that members of the managemen

  • Business Wire4 months ago

    Arcus Biosciences Appoints Kristen M. Hege, M.D., to its Board of Directors

    Arcus Biosciences, Inc. (RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced the appointment of Kristen M. Hege, M.D., to its Board of Directors. Dr. Hege brings more than 20 years of oncology clinical leadership experience to Arcus’s board. “We are thrilled to welcome Dr. Hege to our Board of Directors,” said Terry Rosen, Ph.D., Chief Executive Officer at Arcus.

  • Simply Wall St.4 months ago

    Do You Know Who Else Invests In Arcus Biosciences Inc (NYSE:RCUS)?

    If you want to know who really controls Arcus Biosciences Inc (NYSE:RCUS), then you’ll have to look at the makeup of its share registry. Institutions often own shares in more Read More...

  • Business Wire4 months ago

    Arcus Biosciences to Present Final Results from the Phase 1 Study of AB928 in Healthy Volunteers at ESMO 2018 Congress

    Arcus Biosciences, Inc. (RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that it will present final results from the Phase 1 study of AB928, its dual adenosine receptor antagonist, in healthy volunteers during a poster display session at the European Society of Medical Oncology (ESMO) 2018 Congress, being held October 19-23, 2018, in Munich, Germany. The safety data to be presented will demonstrate that in this study, there was no evidence of the physiological effects of blocking adenosine that have been observed clinically with earlier adenosine receptor antagonists. Physiological effects associated with the earlier adenosine receptor antagonists that were initially designed for CNS indications may potentially limit their optimal dosing in the oncology setting.

  • Business Wire4 months ago

    Arcus Biosciences Announces Nine Abstracts Accepted for Presentation at the SITC 2018 Annual Meeting

    Arcus Biosciences, Inc. , a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that nine abstracts have been accepted for poster presentation at the Society for Immunotherapy of Cancer Annual Meeting, which is being held from November 7-11, 2018 in Washington, D.C.

  • 24 Bay Area companies have gone public so far this year. Here's how they've done.
    American City Business Journals5 months ago

    24 Bay Area companies have gone public so far this year. Here's how they've done.

    The flood of local IPOs passed last year's total of 15 in July and appears well on its way to top the recent high 34 in 2014, with four more coming this week. Here's how the stocks from this year's crop of new Bay Area public companies have performed so far.

  • Business Wire5 months ago

    Arcus Biosciences Announces Participation at Leerink Partners Roundtable Series: Rare Disease & Oncology

    Arcus Biosciences, Inc. , a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced Terry Rosen, Ph.D., Chief Executive Officer, and Jennifer Jarrett, Chief Operating Officer and Chief Financial Officer, will participate in a fireside chat at the Leerink Partners Roundtable Series: Rare Disease & Oncology on Wednesday, October 3, 2018, at 10:30 ...

  • GuruFocus.com6 months ago

    Arcus Biosciences Inc (RCUS) CEO Terry J Rosen Bought $280,407 of Shares

    CEO of Arcus Biosciences Inc (NYSE:RCUS) Terry J Rosen bought 18,607 shares of RCUS on 08/28/2018 at an average price of $15.07 a share.

  • Business Wire6 months ago

    Arcus Biosciences Announces Participation at Two Investor Conferences in September

    Arcus Biosciences, Inc. , a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced the Company will be participa

  • Business Wire6 months ago

    Arcus Biosciences Announces Second Quarter 2018 Financial Results and Recent Corporate Updates

    - Initiated the Phase 1/1b program for AB928 combinations; Initial dose-escalation data for all four combinations expected in the first half of 2019 -

  • Business Wire7 months ago

    Arcus Biosciences to Participate in the 2018 Wedbush PacGrow Healthcare Conference

    Arcus Biosciences, Inc. , a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that Terry Rosen, Ph.D., Chief Executive Officer, will participate in a fireside chat at the 2018 Wedbush PacGrow Healthcare Conference on Tuesday, August 14, 2018 at 2:30 pm ET at the Parker New York, in New York City, NY.

  • Business Wire7 months ago

    Arcus Biosciences Announces Initiation of Phase 1 Trial for AB154, its Anti-TIGIT Antibody

    AB154 is the Company’s third product candidate to enter clinical development. “The initiation of clinical testing for AB154 represents another significant milestone for the Company, as we believe that anti-TIGIT antibodies have the potential to be a new and important class of backbone therapy in immuno-oncology,” said Terry Rosen, Ph.D., Chief Executive Officer at Arcus. “TIGIT is a unique immune checkpoint target, because it is involved in a pathway that plays both immune inhibitory and stimulatory roles in the tumor microenvironment.

  • Why resTORbio Stock Is Seeing Solid Growth Today
    Market Realist7 months ago

    Why resTORbio Stock Is Seeing Solid Growth Today

    Today, resTORbio (TORC) is trading at $13.36, which represents ~48.28% growth compared to yesterday. On July 24, resTORbio stock closed at $9.01, which represents ~19% growth from its 52-week low of $7.54 on April 10. TORC hit its 52-week high of $21.09 on February 26. Today, resTORbio announced positive results from its Phase 2b trial of RTB101 to evaluate the safety and efficacy of the drug in older individuals who are at high risk of morbidity and mortality due to respiratory tract infections.

  • Business Wire7 months ago

    Arcus Biosciences Announces Final Safety Results From Phase 1 Trial for AB928 in Healthy Volunteers

    Arcus Biosciences, Inc. (RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced the final unblinded safety data from its Phase 1 trial for AB928, its dual adenosine receptor antagonist, in healthy volunteers. Pharmacokinetic and pharmacodynamic data from this trial were previously presented in April at the 2018 American Association for Cancer Research (AACR) Annual Meeting. In addition, pharmacodynamic data from this trial demonstrated that an AB928 dose between 75 mg and 150 mg once-daily should be sufficient to achieve greater than 90% inhibition of the adenosine 2a (A2a) receptor pathway,” said Joyson Karakunnel, MD, MSc, FACP, Vice President of Clinical Development at Arcus.

  • Business Wire7 months ago

    Arcus Biosciences Announces That Taiho Pharmaceutical Has Exercised Its Option to Develop and Commercialize AB928 in Its Territories

    Arcus Biosciences, Inc. (RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that Taiho Pharmaceutical Co., Ltd. (Taiho) exercised its option under the Option and License Agreement entered into in September 2017 (Taiho Agreement) to obtain an exclusive development and commercialization license to the Company’s adenosine receptor antagonist program, which includes AB928 and back-up compounds, in Japan and certain other territories in Asia (excluding China). In addition to an option exercise payment, Arcus is eligible to receive clinical and regulatory milestones totaling up to $130 million as well as commercialization milestones and royalties on net sales for this program.

  • Arcus Biosciences and Infinity Pharmaceuticals Announce Clinical Collaboration to Evaluate Lead Programs in Triple-Combination Studies
    PR Newswire8 months ago

    Arcus Biosciences and Infinity Pharmaceuticals Announce Clinical Collaboration to Evaluate Lead Programs in Triple-Combination Studies

    HAYWARD, Calif. and CAMBRIDGE, Mass., June 26, 2018 /PRNewswire/ -- Arcus Biosciences, Inc. (RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, and Infinity Pharmaceuticals, Inc. (INFI), a clinical-stage biopharmaceutical company developing IPI-549, a first-in-class immuno-oncology product candidate that selectively inhibits phosphoinositide-3-kinase gamma (PI3K-gamma), today announced that they have entered into a clinical collaboration to evaluate two triple combination therapies in selected tumor types which typically show minimal response to checkpoint inhibition monotherapy. The collaboration will evaluate IPI-549 in combination with AB928, Arcus's dual adenosine receptor antagonist, and AB122, Arcus's anti-PD-1 antibody, as well as IPI-549 in combination with AB928 and chemotherapy in patients with triple negative breast cancer (TNBC) or ovarian cancer in four separate cohorts.